Pharmacy Times

JUNE 19, 2025

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Pharmacy Times

JUNE 9, 2025

2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 29

Express Pharma

JULY 10, 2024

India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. million and contributes around $1.4

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

pharmaphorum

NOVEMBER 10, 2022

We can talk all the time, Montserrat said, but now is the time for action: early diagnosis, access to the best treatments, innovation, in addition to protection of intellectual property (IP), and after that biosimilars and generics. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity.

Vaccines 97

Vaccines Biosimilars Labelling Pharmaceutical Companies 97

Pharmacy Times

JUNE 19, 2025

million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. A steady increase in CVD-related deaths resulted in approximately 18.6 1 CVDs are disorders affecting the heart and blood vessels.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Hospitals Diabetes 26

PharmaShots

APRIL 3, 2023

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Express Pharma

FEBRUARY 5, 2025

Looming patent expiries Patent expirations have been a significant opportunity for the Indian pharma space that is dominated by generics and biosimilars manufacturing. This trend is likely to continue as these companies continue to build a portfolio of branded specialty products and biosimilars.

Biosimilars 90

Biosimilars Drug Development Vaccines 90

Express Pharma

FEBRUARY 10, 2025

Indias pharma exports are projected to grow from $27 billion in 2023 to $65 billion by 2030 and could reach an estimated $350 billion by 2047. Innovation, including the shift towards specialty generics, biosimilars, and novel products, will be the key to Indias pharmaceutical future. Indian biosimilar exports, valued at ~$0.8

Biosimilars 98

Biosimilars Vaccines 98

Express Pharma

MARCH 21, 2025

Hyderabad leads in bulk drug manufacturing, advanced biopharma research, and vaccine innovation, serving as the base for renowned international players. As Hyderabad aims to expand its life sciences sector from $100 billion to $250 billion by 2030, adopting an integrated research campus model could be the key to achieving this growth.

Vaccines 66

Vaccines Biosimilars Drug Development 66

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105